First Time Loading...

JiangSu WuZhong Pharmaceutical Development Co Ltd
SSE:600200

Watchlist Manager
JiangSu WuZhong Pharmaceutical Development Co Ltd Logo
JiangSu WuZhong Pharmaceutical Development Co Ltd
SSE:600200
Watchlist
Price: 9.65 CNY 1.37%
Updated: Jun 10, 2024

JiangSu WuZhong Pharmaceutical Development Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

JiangSu WuZhong Pharmaceutical Development Co Ltd
Net Income (Common) Peer Comparison

Comparables:
H
3692
600436
600276
000538
S
688506

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
JiangSu WuZhong Pharmaceutical Development Co Ltd
SSE:600200
Net Income (Common)
-¥95m
CAGR 3-Years
39%
CAGR 5-Years
20%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Net Income (Common)
¥3.3B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Net Income (Common)
¥3B
CAGR 3-Years
19%
CAGR 5-Years
20%
CAGR 10-Years
21%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Net Income (Common)
¥4.4B
CAGR 3-Years
-12%
CAGR 5-Years
1%
CAGR 10-Years
13%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Net Income (Common)
¥4.3B
CAGR 3-Years
-5%
CAGR 5-Years
-2%
CAGR 10-Years
6%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Net Income (Common)
-¥780.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is JiangSu WuZhong Pharmaceutical Development Co Ltd's Net Income (Common)?
Net Income (Common)
-95m CNY

Based on the financial report for Mar 31, 2024, JiangSu WuZhong Pharmaceutical Development Co Ltd's Net Income (Common) amounts to -95m CNY.

What is JiangSu WuZhong Pharmaceutical Development Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
20%

Over the last year, the Net Income (Common) growth was -71%. The average annual Net Income (Common) growth rates for JiangSu WuZhong Pharmaceutical Development Co Ltd have been 39% over the past three years , 20% over the past five years .